literature

HIV mutation literature information.

Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.

PMID: 17062187 2006 International journal of STD & AIDS

Abstract: Mutations at codons M184V and Q151M conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-1 infection were detected, as were mutations at codons V71I and L90M implying indinavir and nelfinavir resistance as well.

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.

PMID: 17072129 2006 The Pediatric infectious disease journal

Abstract: BACKGROUND: We retrospectively studied the effect of the lamivudine-induced reverse transcription mutation M184V on selection of thymidine analog mutations (TAMs) in HIV subtype C-infected children and on clinical outcome.

Abstract: In M184V-containing samples, we found large reductions in susceptibility to lamivudine and emtricitabine but not to other NRTIs.

Abstract: RESULTS: M184V developed in 18 of 22 of children who had received only zidovudine/stavudine + lamivudine + PI/NNRTI during a mean of 23.2 +/- 3.2 months versus in 3 of 14 children treated with other drugs and/or having multiple regimen changes (P = 0.001).

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.

PMID: 17096474 2006 The AIDS reader

Abstract: The M184V mutation is selected by lamivudine (3TC) and emtricitabine (FTC) and is a common mutation in HIV-infected patients.

Abstract: Virus with the M184V mutation has a high level of resistance to 3TC and FTC but has been shown to have favorable effects on the susceptibility of some other NRTIs and can delay clinical and immunologic progression by decreasing viral fitness.

Abstract: While it is always better not to have any drug resistance so that 3TC and FTC are available as active antiretroviral agents, it is important to take advantage of the beneficial effects of the M184V mutation when it is present.

Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.

PMID: 17209764 2006 AIDS research and human retroviruses

Abstract: M184V was the most frequent resistance mutation (75.4%), followed by T215Y (52.5%) and K65R (14.8%).

Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs.

PMID: 15550379 2005 The Journal of biological chemistry

Abstract: Here, we extend this property to BH3-d4TTP and BH3-3TCTP toward their clinically relevant mutants Q151M and M184V, respectively.

Abstract: Likewise, resistance to 3TCTP by M184V RT (30-fold) and K65R/M184V RT (180-fold) is suppressed using BH3-3TCTP because of a 160-fold acceleration of the catalytic constant kpol.

Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.

PMID: 15572008 2005 Journal of clinical virology

Abstract: All ten samples with the M184V mutation, three with the K65R, two with the G190A mutation, one with the K103N mutation, and one with the V75T mutation were detected similarly by all three assays.

Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

PMID: 15613309 2005 Journal of virology

Abstract: Following infection of P4 cells, the BV34 mutant, but not viruses expressing the M184V mutation or M41L+T215Y, exhibited a defect in DNA synthesis.

Abstract: Importantly, however, for mutants carrying the M184V mutation or M41L+T215Y mutations, a defect could be detected by using target cells in which dATP pools had been reduced by pretreatment with hydroxyurea.

Abstract: Three recombinant viruses derived from three pNL4-3 molecular clones expressing mutations associated with resistance to zidovudine: a clone expressing RT mutation M184V, a clone expressing mutations M41L plus T215Y (M41L+

Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.

PMID: 15616314 2005 Antimicrobial agents and chemotherapy

Abstract: Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) derivatives with D113E, Y115F, F116Y, Q151E/N, and M184V mutations were studied for their phosphorolysis-mediated resistance to the nucleoside RT inhibitors (NRTIs) zidovudine and stavudine and for their inhibition by the nonnucleoside analogs (NNRTIs) efavirenz and nevirapine.

Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.

PMID: 15627034 2005 AIDS (London, England)

Abstract: Seven primary mutations, V106A (one), Y181C (two), G190A (one), K101E (one), M184V (one), T215S (one) were detected in five (13%) women.

Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.

PMID: 15648062 2005 Journal of medical virology

Abstract: As in HIV-1, substitution M184V was found in 3TC-treated patients.